A higher body mass index and fat mass are factors predictive of docetaxel dose intensity

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5655-5662

  Gouérant, Sophie ^a,b   Leheurteur, Marianne ^a   Chaker, Maher ^a   Modzelewski, Romain ^a   Rigal, Olivier ^a   Veyret, Corinne ^a   Lauridant, Géraldine ^c   Clatot, Florian ^a,d  

^a CENTRE HENRI BECQUEREL   (France)

^b Cancer Institute   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d Normandie University   (France)

Author keywords

Docetaxel; Dose intensity; Early breast cancer; Fat mass; Obesity; Toxicity

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; BODY COMPOSITION; BODY MASS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; FAT MASS; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HEART EJECTION FRACTION; HUMAN; KIDNEY DYSFUNCTION; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OBESITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTOPENIA; TOXICITY TESTING;

EID: 84891395739     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM and Baade PD: The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 36: 237-248, 2012.
2. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M and Pritchard K: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379: 432-444, 2012.
3. Du Bois D and Du Bois EF: A formula to estimate the approximate surface area if height and weight be known. Nutrition 5: 303-311; discussion 312-303, 1989.
4. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB and Sparreboom A: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 94: 1883-1888, 2002.
5. Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J and Baker SD: Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25: 4707-4713, 2007.
6. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG and Sawyer MB: Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13: 3264-3268, 2007.
7. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E and Sawyer MB: Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15: 2920-2926, 2009.
8. Kopelman PG: Obesity as a medical problem. Nature 404: 635-643, 2000.
9. Renehan AG, Tyson M, Egger M, Heller RF and Zwahlen M: Body mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371: 569-578, 2008.
10. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien D, Collins J, Snyder R, Thurlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD and Goldhirsch A: Body mass index as a prognostic feature in operable breast cancer: The International Breast Cancer Study Group experience. Ann Oncol 15: 875-884, 2004.
11. Griggs JJ, Sorbero ME and Lyman GH: Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165: 1267-1273, 2005.
12. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE and Lyman GH: Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 30: 1553-1561, 2012.
13. Edge SB, American Joint Committee on Cancer: AJCC cancer staging manual. 7th edition. New York: Springer; 2010.
14. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC and Zielinski C: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42: 2433-2453, 2006.
15. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH and Lichtin AE: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26: 132-149, 2008.
16. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH and Somerfield MR: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28: 4996-5010, 2010.
17. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 4.0. Published: May 28, 2009. http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm#ctc-40.
18. Hryniuk WM, Figueredo A and Goodyear M: Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14 : 3-11, 1987.
19. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ and Baracos VE: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33: 997-1006, 2008.
20. Jenkins P, Elyan S and Freeman S: Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer 43: 544-548, 2007.
21. Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC and Schilsky RL: Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 14: 3000-3008, 1996.
22. Fumoleau P, Roche H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier MJ and Luporsi E: Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 17: 85-92, 2006.
23. Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M and Goldhirsch A: Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 366: 1108-1110, 2005.
24. Poikonen P, Blomqvist C and Joensuu H: Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol 40: 67-71, 2001.
25. De Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjold B, Gutierez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A and Piccart-Gebhart M: The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 119: 145-153, 2010.
26. Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjold B, Lang I, Jakesz R, Vorobiof D, Gutierrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M and Piccart-Gebhart M: Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100: 121-133, 2008.
27. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N and Marty M: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037-1042, 1993.
28. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM and Sheiner LB: Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187-196, 1998.
29. Felici A, Verweij J and Sparreboom A: Dosing strategies for anticancer drugs: The good, the bad and body surface area. Eur J Cancer 38: 1677-1684, 2002.
30. Blouin RA and Warren GW: Pharmacokinetic considerations in obesity. J Pharm Sci 88: 1-7, 1999.
31. Hanley MJ, Abernethy DR and Greenblatt DJ: Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49: 71-87, 2010.
32. Cheymol G: Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 25: 103-114, 1993.